Lansoprazole (Aspen Lansoprazole, Aspen-lansoprazole)
Lansoprazole
Pharmacare limited û woodmead
Registration
- Applicant
- Pharmacare limited û woodmead
- Certificate holder
- Pharmacare limited
- Registrations
- 2
- Schedule source
- SAHPRA documentation
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Aspen lansoprazole 30 EACH CAPSULE CONTAINS LANSOPRAZOLE 30,0 mg | 15MG/30MGCapsules | 37015437/11.4.3/0154Approved 25 May 2020 | Registered | S4 | PI |
| Aspen-lansoprazole 15 EACH CAPSULE CONTAINS LANSOPRAZOLE 15,0 mg | 15 | 37023737/11.4.3/0237 | Registered | Not determined | None |
Regulatory status
Where S4 sits on the scale
Prescription-only medicine.
Schedule 4 covers most ordinary prescription medicines. You need a prescription from an authorised prescriber, such as a doctor or dentist, and a pharmacist dispenses it. Its price, name, pack size and strength can still be told to the public, as long as nothing links it to what it treats.
Schedule S4, read from the product's PI-PIL leaflet.
Who may supply: A pharmacist dispensing against a written or verbal prescription from an authorised prescriber; a veterinarian, who may also prescribe, compound or dispense it directly; a medical practitioner or dentist, who may prescribe it and may compound or dispense it directly only if licensed under section 22C(1)(a); manufacturers and wholesalers may supply people who may lawfully possess it; and, for animal treatment, a person practising a para-veterinary profession, on a veterinarian's written or verbal instruction.
Consolidated Schedules listings for Lansoprazole
S4: Lansoprazole
- except when intended for the temporary short-term relief of heartburn and hyperacidity, subject to:
- a maximum daily dose of 15 milligrams (S2); and
- a maximum treatment period of 14 days. (S2)
Consolidated Schedules 06 July 2026, lines 6854 to 6857
S2: Lansoprazole
- when intended for the temporary short-term relief of heartburn and hyperacidity, subject to –
- maximum daily dose of 15 milligrams
- maximum treatment period of 14 days. (S4)
Consolidated Schedules 06 July 2026, lines 2224 to 2228
Pharmacological class: Other. (class 11.4.3)
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
2-[[3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methylsulfinyl]-1H-benzimidazole
Drag to rotate. Structure from PubChem CID 3883.
SAHPRA documents
Schedule Verification
This medication's schedule (S4) has been verified from official SAHPRA documents with 90% confidence.
These documents are provided by SAHPRA for informational purposes. Always consult with a healthcare professional for medical advice.